NCT06716970

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

A Multicenter, Randomized, Double-blind, and Active-controlled Parallel Study to Evaluate the Efficacy and Safety of QR12000 Compound Tablets and Sacubitril/valsartan Tablets in Patients with Moderate to Severe Essential Hypertension

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 810 (estimated)
• Sponsor: Wuhan Createrna Science and Technology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	QR12000 75mg	QR12000 75mg QD
DRUG	QR12000 75mg placebo	Matching placebo of QR12000 75mg QD
DRUG	QR12000 150mg	QR12000 150mg QD
DRUG	QR12000 150mg placebo	Matching placebo of QR12000 150mg QD
DRUG	Sacubitril/valsartan 200mg	Sacubitril/valsartan 200mg QD
DRUG	Sacubitril/valsartan 200mg placebo	Matching placebo of Sacubitril/valsartan 200mg QD

Timeline

• Start date: 2024-12-30
• Primary completion: 2026-04-30
• Completion: 2027-02-28
• First posted: 2024-12-04
• Last updated: 2024-12-06

Locations

1 site across 1 country: China